Rajesh Krishnamoorthi1, Babu P Mohan2, Mahendran Jayaraj3, Kenneth K Wang4, David A Katzka4, Andrew Ross1, Douglas G Adler5, Prasad G Iyer4. 1. Digestive Diseases Institute, Virginia Mason Medical Center, Seattle, Washington, USA. 2. Internal Medicine, Banner University Medical Center, University of Arizona, Tucson, Arizona, USA. 3. Department of Gastroenterology and Hepatology, University of Nevada, Las Vegas, Nevada, USA. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. 5. Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, Salt Lake City, Utah, USA.
Abstract
BACKGROUND AND AIMS: Risk of progression in Barrett's esophagus (BE) with low-grade dysplasia (LGD) and high-grade dysplasia (HGD) has been established. However, the natural history of BE with indefinite dysplasia (BE-IND) remains unclear. We performed a systematic review and meta-analysis to estimate the pooled risk of progression to HGD and/or esophageal adenocarcinoma (EAC) in BE-IND. METHODS: We performed a systematic search of multiple databases to June 2018 to identify studies reporting the incidence of HGD, EAC, or HGD/EAC as an outcome in patients with BE-IND undergoing endoscopic surveillance. The pooled incidence rate of HGD and/or EAC and EAC alone was estimated. RESULTS: We identified 8 studies reporting the incidence of HGD and/or EAC and 5 studies reporting the incidence of EAC in BE-IND. The pooled incidence of HGD and/or EAC (89 cases in 1441 patients over 5306.2 person-years) was 1.5 per 100 person-years (95% confidence interval [CI], 1.0-2.0). The pooled incidence of EAC (40 cases in 1266 patients over 4520.2 person-years) was 0.6 per 100 person-years (95% CI, 0.1-1.1). Substantial heterogeneity was noted in the analyses. On subgroup analysis, the incidence of EAC was higher in studies from Europe compared with North America (0.9% vs 0.1%, P = .01). The pooled incidence of LGD was 11.4 per 100 person-years (95% CI, 0.06-0.2). CONCLUSION: The estimated incidence of HGD and/or EAC and EAC alone in BE-IND is similar to the previously reported progression risk in BE-LGD. Based on these risk estimates, patients with BE-IND should be placed on active endoscopic surveillance.
BACKGROUND AND AIMS: Risk of progression in Barrett's esophagus (BE) with low-grade dysplasia (LGD) and high-grade dysplasia (HGD) has been established. However, the natural history of BE with indefinite dysplasia (BE-IND) remains unclear. We performed a systematic review and meta-analysis to estimate the pooled risk of progression to HGD and/or esophageal adenocarcinoma (EAC) in BE-IND. METHODS: We performed a systematic search of multiple databases to June 2018 to identify studies reporting the incidence of HGD, EAC, or HGD/EAC as an outcome in patients with BE-IND undergoing endoscopic surveillance. The pooled incidence rate of HGD and/or EAC and EAC alone was estimated. RESULTS: We identified 8 studies reporting the incidence of HGD and/or EAC and 5 studies reporting the incidence of EAC in BE-IND. The pooled incidence of HGD and/or EAC (89 cases in 1441 patients over 5306.2 person-years) was 1.5 per 100 person-years (95% confidence interval [CI], 1.0-2.0). The pooled incidence of EAC (40 cases in 1266 patients over 4520.2 person-years) was 0.6 per 100 person-years (95% CI, 0.1-1.1). Substantial heterogeneity was noted in the analyses. On subgroup analysis, the incidence of EAC was higher in studies from Europe compared with North America (0.9% vs 0.1%, P = .01). The pooled incidence of LGD was 11.4 per 100 person-years (95% CI, 0.06-0.2). CONCLUSION: The estimated incidence of HGD and/or EAC and EAC alone in BE-IND is similar to the previously reported progression risk in BE-LGD. Based on these risk estimates, patients with BE-IND should be placed on active endoscopic surveillance.
Authors: Sumeet K Mittal; Joe Abdo; Malika P Adrien; Binyam A Bayu; Jay R Kline; Molly M Sullivan; Devendra K Agrawal Journal: J Gastrointest Oncol Date: 2021-08
Authors: D Chamil Codipilly; Apoorva Krishna Chandar; Kenneth K Wang; David A Katzka; John R Goldblum; Prashanthi N Thota; Gary W Falk; Amitabh Chak; Prasad G Iyer Journal: Gastrointest Endosc Date: 2021-09-17 Impact factor: 9.427
Authors: Theresa H Nguyen; Aaron P Thrift; Rollin George; Daniel G Rosen; Hashem B El-Serag; Gyanprakash A Ketwaroo Journal: Clin Gastroenterol Hepatol Date: 2021-04-08 Impact factor: 11.382
Authors: Richard Phillips; Wladyslaw Januszewicz; Nastazja D Pilonis; Maria O'Donovan; Tarek Sawas; David A Katzka; Rebecca C Fitzgerald; Massimiliano di Pietro Journal: Gastrointest Endosc Date: 2021-02-04 Impact factor: 9.427
Authors: Wladyslaw Januszewicz; Nastazja D Pilonis; Tarek Sawas; Richard Phillips; Maria O'Donovan; Ahmad Miremadi; Shalini Malhotra; Monika Tripathi; Adrienn Blasko; David A Katzka; Rebecca C Fitzgerald; Massimiliano di Pietro Journal: Histopathology Date: 2022-06 Impact factor: 7.778